Clinical efficacy and safety of omalizumab in conventional treatment‐resistant vernal keratoconjunctivitis: Our experience and literature review.
Parisi, Giuseppe Fabio
Marseglia, Gian Luigi
TUMOR necrosis factor
Immunity, Inflammation & Disease; Mar2021, Vol. 9 Issue 1, p3-7, 5p
Vernal keratoconjunctivitis (VKC) is a severe ocular disease characterized by recurring acute and/or chronic corneal-conjunctival inflammation leading to visual sequelae.1 Since no treatments are universally effective in the management of VKC, novel therapies are currently under investigation, including anti-immunoglobulin E (IgE). Although the efficacy and safety of omalizumab have been assessed in the therapeutic management of IgE-mediated disorders2-7; literature data on the use of omalizumab in VKC are very sparse.8-13 Herein, we reported the use of omalizumab in treating conventional treatment-resistant VKC unresponsive in two children. As well as Patient 1, we started treatment with omalizumab (600 mg every 14 days), reporting significant improvement in clinical symptoms, in severity disease, in need for rescue therapies, and in ocular examination findings (Figure 2). [Extracted from the article]
Copyright of Immunity, Inflammation & Disease is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.